Literature DB >> 3140772

Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits.

T P O'Brien1, M R Sawusch, J D Dick, J D Gottsch.   

Abstract

Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 X 10(2) aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 X 10(7) organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140772     DOI: 10.1001/archopht.1988.01060140608032

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  6 in total

1.  Topical pefloxacin in bacterial keratitis.

Authors:  R B Vajpayee; N Sharma; B Verma; M Vajpayee; S K Gupta; G Satpathy; R Saxena
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora.

Authors:  J P Leeming; J P Diamond; R Trigg; L White; H B Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 3.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Interventions and Outcomes in Patients with Infectious Pseudomonas scleritis: A 10-Year Perspective.

Authors:  Sumayya Ahmad; Michelle Lopez; Marwan Attala; Anat Galor; Natalie A Stanciu; Darlene Miller; Leejee Suh; Thomas Albini; Victor L Perez; Carol L Karp; Janet L Davis; Eduardo Alfonso; Richard K Forster; Guillermo Amescua
Journal:  Ocul Immunol Inflamm       Date:  2017-10-17       Impact factor: 3.070

5.  Bacterial keratitis: a prospective clinical and microbiological study.

Authors:  F Schaefer; O Bruttin; L Zografos; Y Guex-Crosier
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 6.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.